From darkness to light with biomarkers in early clinical trials of cancer drugs

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 2, 2009, Pages 131-133

  Carden, C P ^a,b   Banerji, U ^a,b   Kaye, S B ^a,b   Workman, P ^a,b   De Bono, J S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; AZD 22281; BIOLOGICAL MARKER; BORTEZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME; PROTEIN P110; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BRCA GENE; BREAST CANCER; CANCER THERAPY; CLINICAL STUDY; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GENE; GENE MUTATION; HAIR FOLLICLE; HUMAN; MAXIMUM TOLERATED DOSE; ONCOGENE; PATIENT PARTICIPATION; PATIENT SELECTION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGNOSIS; PTEN GENE; SHORT SURVEY; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DARKNESS; HUMANS; LIGHT; NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 58449087275     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.223     Document Type: Short Survey

References (14)

1. Kamb, A., Wee, S. & Lengauer, C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 6, 115-120 (2007).
2. Banerj, U. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23, 4152-4161 (2005).
3. Fong, P. et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J. Clin. Oncol. 26, 1 (2008).
4. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
5. Woodcock, J. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development 〈http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4079S2-03- Woodcock.ppt〉 (2004).
6. Sarker, D. & Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 96, 213-268 (2007).
7. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
8. Yap, T.A., Garrett, M.D., Walton, M.I., Raynaud, F., de Bono, J.S. & Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393-412 (2008).
9. Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. USA 105, 692-697 (2008).
10. Rothenberg, M.L. et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol. 23, 9265-9274 (2005).
11. Orlowski, R.Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002).
12. Olmos, D. et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol. (2008); e-pub ahead of print 11 August 2008.
13. de Bono, J. S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostrate cancer. Clin. Cancer Res. 14, 6302-6309 (2008)
14. Workman, P. et al. Minimally invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypotheses-Testing Clinical Trials of Innovative Therapies. JNCI 98,580-598 (2006).